ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
February 03 2016 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops novel anticancer therapeutics
using its antibody-drug conjugate (ADC) technology, today announced
that the following presentations by Company management at upcoming
investor conferences will be webcast:
- Leerink Partners 5th
Annual Global Healthcare Conference2:40 pm ET, February
10
- RBC Capital Markets Global
Healthcare Conference11:30 am ET, February 23
- Cowen and Company 36th
Annual Health Care Conference9:20 am ET, March 8
The webcasts will be accessible live through the “Investors”
section of the Company’s website, www.immunogen.com; a replay will
be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company's lead product candidate, mirvetuximab
soravtansine, is a potential treatment for folate receptor
α-positive ovarian cancer and other solid tumors. A number of major
healthcare companies have licensed limited rights to use
ImmunoGen's ADC technology to develop anticancer therapies; it is
used in Roche's marketed product, Kadcyla®. More information about
the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160203005095/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024